Physician profile
Amir Wind
NPI 1174588420
$605.19
in general payments reported to CMS, 2019-2025
18 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $77.21 · 2023: $115 · 2024: $178 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $83.61 | 2023-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $74.37 | 2023 | Jornay Pm |
| Novo Nordisk INC | $73.67 | 2021-2025 | Wegovy |
| Cranial Technologies, INC | $66.77 | 2022-2024 | Doc Band |
| Pfizer INC. | $43.17 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.23 | 2021 | |
| Noven Therapeutics, LLC | $24.79 | 2024 | Xelstrym |
| Astellas Pharma US INC | $24.70 | 2024 | Veozah |
| Spr Therapeutics, INC | $23.37 | 2024 | Sprint Pns System |
| Supernus Pharmaceuticals, INC. | $23.20 | 2025 | Qelbree |
| Organon LLC | $22.28 | 2022 | |
| Merck Sharp & Dohme LLC | $21.49 | 2024 | Vaxelis, Gardasil, Vaxneuvance |
| Cipher Pharmaceuticals US LLC | $20.19 | 2025 | Natroba, Spinosad |
| Biomarin Pharmaceutical INC. | $17.88 | 2025 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals Lp | $16.85 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $15.61 | 2021 | |
| Lilly USA, LLC | $13.72 | 2021 | |
| Medtronic, INC. | $13.29 | 2024 | Kyphon Express II Kyphopak Tray |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Wind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.